Medicated feed premix manufacturing for growing swine and broiler poultry places the veterinary API mixture into a Type A medicated article governed by FDA 21 CFR 558.3 and 21 CFR 225, with EU production sites additionally bound by Regulation 2019/4. The mixture is received against a particle-size specification of 90% < 150 µm and a loss on drying below 2.0%; warehousing is maintained below 25 °C and 60% relative humidity to prevent moisture uptake that would otherwise reduce flowability through a bin gate. The first dilution step uses a 1,500 L horizontal ribbon mixer operating at 28–36 rpm, in which the API mixture is blended with a lactose monohydrate or ground corncob carrier to achieve a Type A concentration of 5–15% w/w, depending on the approved species-specific potency. Mixer performance is validated through stratified sampling across 10 points; acceptance for the Type A premix requires a relative standard deviation below 5.0%, with no single result deviating more than 10% from the target active content.

The formulation addition ratio in the complete feed is derived from the approved dose for the target species rather than fixed at the API-mixture stage. A Type A premix with 10% w/w API-mixture loading is commonly metered at 5–20 kg per tonne of complete feed, giving a final active-mixture concentration of 0.05–0.2% w/w; the exact metering rate is set by the target animal body-weight dose, the number of animals per pen, and the medicated feeding duration stated in the marketing authorisation. Production-scale bottlenecks occur when the micro-ingredient metering screw has a minimum discharge of 0.5 kg, because a low-dosage formula with a short batch length falls below the scale’s accuracy window of ±2%; in such cases, a Type B intermediate pre-blend is produced to bring the metering mass into the validated range.

Regulation 2019/4 requires validated cleaning and carryover control for medicated feed lines. The general carryover limit for non-target feed is 1% of the active substance present in the previous batch, while coccidiostats and histomonostats are subject to a 3% limit; stricter species-specific restrictions may be imposed by the marketing authorisation. Terminal finished product types include a Type A medicated article packed in 25 kg multi-layer paper sacks, Type B intermediate pre-blends for feed mills, and Type C complete feed in mash, extruded pellet, or crumble form.

What Happens When a Poorly Soluble Veterinary API Mixture Enters a Hard Capsule Fill?

Under EU Regulation 2019/6 and FDA 21 CFR 211, tablets and capsules for companion animals are manufactured in a solid-dosage suite with negative air pressure relative to adjacent corridors and a room air change rate of 20–25 air changes per hour. The API mixture is pre-milled through a conical mill fitted with a 0.457 mm screen and then dry-blended with microcrystalline cellulose (20–35% w/w), lactose monohydrate (15–25% w/w), croscarmellose sodium (2–4% w/w), and magnesium stearate (0.5–1.0% w/w). The formulation addition ratio for the API mixture in a direct compression matrix is typically 10–40% w/w; when densified by roller compaction, the compacted granules are blended with extragranular disintegrant and lubricant at an API load up to 60% w/w. Wet granulation in a 300 L high-shear bowl is used only when the API mixture displays a Carr index above 30 or a Hausner ratio above 1.4, because the water addition window narrows sharply at high active loading and the endpoint torque curve becomes unstable.

Tablets are compressed on a 27-station rotary press to a target hardness of 50–80 N and a friability below 1.0% under Ph. Eur. 2.9.8. Disintegration is evaluated in 37 °C distilled water; acceptance is complete disintegration within 15 minutes unless the SPC specifies a delayed-release profile. Capsule filling uses a dosator or tamping-pin machine; fill weight uniformity under Ph. Eur. 2.9.40 requires an acceptance value below 15. Dissolution testing under USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 M hydrochloric acid is used as a batch-release marker for immediate-release products; published data for this specific multi-active mixture remain formulation-dependent, so the Q value is set by the species-specific dossier rather than a compendial default. The terminal product types include scored tablets, chewable tablets, mini-tablets for small-breed dogs, and hard gelatin capsules in 10, 20, and 50 mg active-mixture strengths.

Injectable Solutions, Filter Compatibility, and the Endotoxin Load Below 0.5 EU/mL

Production of injectable solutions from the veterinary API mixture for cattle, swine, and equine use is conducted under ISO 14644-1 Class 7 background with Class 5 unidirectional-flow filling, following Ph. Eur. 2.6.1 and USP <71> for sterility. The bulk solution is compounded in a 500 L stainless-steel vessel with a bottom-entry high-shear mixer; the API mixture is dissolved or suspended in water for injection containing 10–30% v/v propylene glycol or 10–20% v/v polyethylene glycol 300 when the aqueous solubility of the active components is below 5 mg/mL. The formulation addition ratio for injectable solutions is usually 1–10% w/v; for injectable suspensions, the ratio rises to 5–20% w/v with a particle-size ceiling of 90% < 10 µm and 100% < 30 µm to avoid syringeability failure in 16G needles.

Filtration through a 0.22 µm PVDF or PES membrane serves as a pre-filtration step when the formulation is terminally autoclaved at 121 °C for 15 minutes; for thermolabile active mixtures, aseptic filtration through 0.22 µm is used, and a 0.1 µm membrane may be introduced if mycoplasma risk is identified in the target-species SPC. Filter integrity is tested by bubble point or water intrusion before and after filling. Endotoxin levels are controlled below 0.5 EU/mL under Ph. Eur. 2.6.14 and USP <85>; incoming API mixture is released with a bioburden below 100 CFU/g and endotoxin below 0.25 EU/mg. On commercial lines, the main batch-to-batch variance arises from pH drift after terminal steam contact; active recovery below 95% and visible particulate failures under USP <790> are the two most common rejection causes when a labile component is present without a stabiliser.

Finished product types include single-dose glass vials of 50 mL, 100 mL, and 250 mL, and multi-dose vials of 100 mL preserved with 0.3% w/v benzyl alcohol or 0.2% w/v methyl parahydroxybenzoate. The terminal sterilisation cycle is validated using the overkill approach with biological indicators at F0>15 minutes unless the SPC restricts exposure time; aseptic filling lines use environmental monitoring limits of <5 CFU/plate in the critical zone and a personnel gowning programme aligned with ISO 14644-5.

On poultry farms with closed drinking-water delivery, the veterinary API mixture is converted into a water-soluble granule by top-spray fluid-bed granulation in a Wurster or conical bed, using an aqueous binder solution containing 2–5% w/w polyvinylpyrrolidone K30 or hydroxypropyl methylcellulose. The formulation addition ratio for the API mixture in the dry granule is 20–70% w/w; lactose or dextrose monohydrate serves as the diluent, and sodium bicarbonate or citric acid is added at 1–2% w/w as a pH-modifying dissolution pair for brackish water sources with total hardness above 250 ppm as calcium carbonate. Granulation is controlled to a product temperature of 36–42 °C and an outlet air relative humidity below 35%; the dried granule must pass a 1.0 mm sieve and retain not more than 10% fines below 75 µm to avoid dust and poor wetting.

Wettability under CIPAC MT 53.3 must be below 60 seconds in 30 °C water; when wetting time exceeds 120 seconds, the dosage form fails in automatic dosing pumps because undissolved granules block the 0.5 mm in-line filters. Reconstituted solution stability is tested at 25 °C for 24 hours; active recovery must remain within 95–105% of label claim, and sedimentation volume after 4 hours must be above 0.9. Compliance for poultry drinking-water granules is governed by EU Regulation 2019/6; uniformity of mass under Ph. Eur. 2.9.5 and uniformity of dosage units under Ph. Eur. 2.9.40 are applied to sachet presentations. The terminal product types include 100 g and 1 kg laminated foil sachets, 25 kg bulk drums with desiccant liners, and stock solutions diluted by proportioner pumps at 1:100 to 1:200.

When a Non-Newtonian Suspension Is Required for Ruminant Oral Drench Delivery

When a non-Newtonian suspension is required for ruminant oral drench delivery, the veterinary API mixture is dispersed in an aqueous vehicle containing 0.2–0.8% w/w xanthan gum or 0.5–1.5% w/w sodium carboxymethylcellulose, with 5–10% v/v glycerol or sorbitol added to increase palatability and viscosity. The formulation addition ratio of the API mixture is 2–15% w/v for suspensions and 1–8% w/v for simple solutions; a high-shear rotor-stator homogenizer operating at 3,000–5,000 rpm for 20–30 minutes is used to disperse the solid phase, followed by a 150 µm wet sieve to remove agglomerates. The target apparent viscosity at 20 °C is 300–800 mPa·s at a shear rate of 10 s⁻¹; below 200 mPa·s, suspended API particles sediment within 4 hours, while above 1,200 mPa·s, the drench gun back-pressure exceeds 2.0 bar and repeat dosing accuracy across 1,000 animals declines on commercial farms.

Oral drench products are regulated under EU Regulation 2019/6 and must meet Ph. Eur. 2.9.40 for single-dose drench presentations; preservative efficacy is verified under Ph. Eur. 5.1.3 when multi-dose packaging is used. After storage at 25 °C and 60% relative humidity for 12 months, sediment volume must not fall below 0.8; if it does, the formulation is reworked with a co-processed microcrystalline cellulose and sodium alginate stabiliser. Finished products are supplied in 1 L, 2.5 L, and 5 L high-density polyethylene jerry cans, with a calibrated drench gun delivering 5–20 mL per stroke according to body weight.

For neonatal calves receiving medicated milk replacer, the veterinary API mixture is dry-blended with skim milk powder (40–60% w/w), whey protein concentrate (15–25% w/w), and encapsulated vegetable fat in maltodextrin (10–20% w/w). The formulation addition ratio is kept between 0.05–1.0% w/w of final reconstituted milk replacer, because higher concentrations produce grittiness and reduce calf intake. The blend is mixed in a 500 kg ribbon or paddle mixer at 25 rpm for 8–12 minutes, then filled into 10 kg or 25 kg multi-wall paper sacks with a polyethylene inner liner. Moisture content is controlled below 4.0%; if the API mixture contains hygroscopic components, the room dew point is maintained below 10 °C and the packaging includes a silica gel sachet of 10 g per 25 kg sack.

Products are placed on the market under EU Regulation 2019/6 or FDA 21 CFR 558 provisions for medicated feeds; batch release includes a reconstitution test in warm water at 40 °C and a wet-sieving residue below 0.5% on a 250 µm sieve. The terminal product type is a medicated milk replacer powder, used via nipple bucket or automatic calf feeder at a mixing rate of 150 g/L.